Novo Nordisk, the corporate behind Ozempic and Wegovy, revealed a brand new evaluation of the longest research it has carried out to this point via the lens of long-term weight reduction.
The 17,604-person research, revealed in Nature Medication and introduced on the European Congress on Weight problems in Venice, Italy on Tuesday, confirmed for the primary time that weight problems sufferers with out diabetes maintained a ten% common weight reduction over 4 years after taking Wegovy.
“We see that after the vast majority of the load loss is accrued, you do not return and begin to enhance in weight when you keep on the drug,” Martin Holst Lange, Novo’s improvement head, informed Reuters in an interview.
The findings present that Wegovy is efficient in the long run, over a number of years, supplied sufferers keep on it.
Associated: Novo Nordisk Is Value Extra Than Denmark’s GDP Due to America’s Ozempic and Wegovy Craze
A further evaluation launched Tuesday primarily based on the identical knowledge confirmed that Wegovy had advantages for the guts, no matter how a lot weight research contributors misplaced whereas taking it.
Wegovy lowered the chance of stroke by 20% in chubby or overweight individuals with a historical past of coronary heart illness.
Researchers do not exactly know the way Wegovy’s lively ingredient, semaglutide, protects the guts, and are conducting research to grasp it.
“We now additionally perceive that whereas we all know that physique weight reduction is vital, it isn’t the one factor driving the cardiovascular advantage of semaglutide remedy,” Lange informed Reuters on Tuesday.
Associated: These U.S. Well being Insurers Will Now Cowl Wegovy, the Wildly Fashionable $1,349 Weight-Loss Drug
The information may add to Novo’s case to have its weight reduction medication be extra broadly lined by insurance coverage firms in nations just like the U.S. and the U.Okay.
Nonetheless, there have been downsides to taking Wegovy recorded within the report — about 17% of those that took the drug left the research early due to stomach-related points like nausea.
Novo has made Wegovy out there in 10 nations to this point, together with the U.S., Norway, Japan, and Spain, since releasing the drug in 2021. Costs begin at $200 and might attain nearly $2,000 per 30 days, relying on the nation.
Within the U.S., Ozempic goes for about $936 a month out of pocket whereas Wegovy sells for about $1,350 a month.
Costco created a program in April that offers members direct entry to Ozempic and Wegovy when acceptable, although the treatment value falls immediately on clients or medical health insurance.
Associated: Costco Publicizes Ozempic, Wegovy Prescriptions and New Weight Loss Program
Novo stated earlier this month that not less than 25,000 individuals within the U.S. begin Wegovy per week.
